Eisai seeks FDA priority review for lecanemab to treat early Alzheimer’s Disease
Lecanemab is indicated for mild cognitive impairment (MCI) due to AD and mild AD (collectively early AD), in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 May 22
Lecanemab is indicated for mild cognitive impairment (MCI) due to AD and mild AD (collectively early AD), in…
10 May 22
Sunosi is indicated to improve wakefulness in adult patients suffering from excessive daytime sleepiness (EDS) due to narcolepsy…
09 May 22
The company intends to use the proceeds from the funding to ramp up the ongoing clinical trials of…
09 May 22
Orion will pay an upfront payment of €15m to Jemincare, in addition to certain development, commercialisation and sales…
06 May 22
The US FDA determined that the known and potential benefits of the vaccine for the prevention of Covid-19…
05 May 22
Jazz obtains development and commercialisation rights in the US, Europe and other territories, while Sumitomo Pharma retains rights…
05 May 22
The EC approval is supported by the Phase 2 ELARA trial, which showed that Kymriah has resulted in…
04 May 22
Cabometyx is an inhibitor of the tyrosine kinases c-Met and VEGFR2, discovered and developed by genomics-based drug discovery…
04 May 22
Darolutamide is an oral androgen receptor inhibitor (ARi), developed by the company in partnership with Orion Corp, and…
02 May 22
The US-based firm sought a variation to the CMA from the European Medicines Agency (EMA) to assess a…